{"id":12237,"date":"2026-03-12T15:23:16","date_gmt":"2026-03-12T14:23:16","guid":{"rendered":"https:\/\/pepticoreaminos.net\/?post_type=product&#038;p=12237"},"modified":"2026-05-29T16:47:58","modified_gmt":"2026-05-29T14:47:58","slug":"retatrutide-10mg","status":"publish","type":"product","link":"https:\/\/pepticoreaminos.us\/en\/product\/retatrutide-10mg\/","title":{"rendered":"Retatrutide 10mg"},"content":{"rendered":"<section class=\"pc-product-longdesc\">\n<blockquote>\n<h2>Retatrutide\u00a0 \u2014 Tri-agonista GLP-1 \/ GIP \/ Glucagone<\/h2>\n<\/blockquote>\n<p class=\"translation-block\"><strong>What is Retatrutide?<\/strong>\n<strong>Retatrutide<\/strong> (LY3437943) is a next-generation peptide belonging to the class of <em>incretin mimetics<\/em>. It acts simultaneously on three key hormonal receptors \u2014 <strong>GLP-1<\/strong>, <strong>GIP<\/strong>, and <strong>glucagon<\/strong> \u2014 aiming to synergistically modulate appetite, glucose metabolism, and energy expenditure. This triple mechanism positions it as the potential <strong>successor to tirzepatide<\/strong>, expanding the \u201cdual agonist\u201d concept into a new class of <em>tri-agonists<\/em>. All Pepticore Aminos products are strictly intended for research and laboratory use (<em>Research Use Only<\/em>).<\/p>\n<h3>How it works (GLP-1, GIP, Glucagon)<\/h3>\n<p class=\"translation-block\"><strong>GLP-1<\/strong> (glucagon-like peptide-1) sends satiety signals to the brain, slows gastric emptying, and stimulates insulin secretion in a glucose-dependent manner. It also helps reduce endogenous glucagon release, improving postprandial glucose control.<\/p>\n<p class=\"translation-block\"><strong>GIP<\/strong> (glucose-dependent insulinotropic polypeptide) enhances the insulin response after carbohydrate and fat intake, promoting glucose utilization for energy and reducing hepatic glucose production. Acting synergistically with GLP-1, it supports insulin sensitivity and lipid metabolism.<\/p>\n<p class=\"translation-block\"><strong>Glucagon<\/strong> in this context does not act as an insulin antagonist but as a regulator of energy metabolism. Its controlled activation increases lipolysis and fatty acid oxidation, promoting a <em>higher resting energy expenditure<\/em> and reduction of visceral fat. This triad of mechanisms makes retatrutide a unique research platform for studying complex metabolic balance.<\/p>\n<div class=\"pc-highlight-box\" style=\"background-color: #f5f9f8; border-left: 4px solid #009688; padding: 15px; margin: 20px 0; border-radius: 8px;\">\n<h4 style=\"margin-top: 0;\">\ud83d\udd2c Research Highlights<\/h4>\n<ul style=\"margin: 0; padding-left: 20px;\">\n<li class=\"translation-block\"><strong>\u221224.2%<\/strong> mean body weight reduction after 48 weeks in adults with obesity (Phase 2, NEJM 2023)<\/li>\n<li class=\"translation-block\"><strong>\u22122.16 HbA1c points<\/strong> and ~17% weight loss in T2D after 36 weeks (Phase 2, Lancet 2023)<\/li>\n<li class=\"translation-block\"><strong>\u221281\u201382%<\/strong> liver fat reduction with normalization &lt;5% in the MASLD substudy (Nature Medicine 2024)<\/li>\n<\/ul>\n<\/div>\n<h3>Clinical Evidence (Phase 2)<\/h3>\n<p class=\"translation-block\"><\/h3> <strong>Obesity without diabetes:<\/strong> In the <em>New England Journal of Medicine<\/em> study, retatrutide produced mean weight reductions of <strong>\u221222.8%<\/strong> (8 mg) and <strong>\u221224.2%<\/strong> (12 mg) after 48 weeks, along with improvements in BMI, waist circumference, and blood pressure. See <a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2301972\" target=\"_blank\">NEJM 2023<\/a> \/ <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37366315\/\" target=\"_blank\">PubMed<\/a>.<\/p>\n<p class=\"translation-block\"><strong>Type 2 Diabetes:<\/strong> In the <em>Lancet<\/em> Phase 2 trial, retatrutide reduced HbA1c by up to <strong>\u22122.16 percentage points<\/strong> at the highest doses, accompanied by a robust weight reduction (~17% at 36 weeks). The most frequent adverse events were gastrointestinal (nausea, reduced appetite), generally mild to moderate. See\n<a href=\"https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-67362301053-X\/fulltext\" target=\"_blank\">Lancet 2023<\/a> \/ <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37385280\/\" target=\"_blank\">PubMed<\/a>.<\/p>\n<p class=\"translation-block\"><strong>Liver (MASLD):<\/strong> The <em>Nature Medicine<\/em> substudy reported a relative liver fat reduction of <strong>\u221281\u201382%<\/strong> at 8\u201312 mg doses, with normalization (&lt;5%) in most participants and improvement in inflammation and liver function biomarkers. See\n<a href=\"https:\/\/www.nature.com\/articles\/s41591-024-03018-2\" target=\"_blank\">Nature Medicine 2024<\/a> \/ <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/38858523\/\" target=\"_blank\">PubMed<\/a>.<\/p>\n<h3>Comparison with Semaglutide and Tirzepatide<\/h3>\n<p class=\"translation-block\"><strong>Semaglutide<\/strong> (GLP-1 agonist) achieved ~15% mean weight loss over ~68 weeks; <strong>tirzepatide<\/strong> (GLP-1+GIP agonist) reached ~22.5% over ~72 weeks. <strong>Retatrutide<\/strong>, through additional glucagon receptor activation, achieved ~<strong>24%<\/strong> in 48 weeks. Although not head-to-head comparisons, these results show a progressive enhancement of efficacy across incretin-agonist generations, positioning retatrutide as a likely pharmacological evolution of tirzepatide.<\/p>\n<div class=\"table-wrapper\" style=\"margin: 16px 0;\">\n<table>\n<thead>\n<tr>\n<th>Drug<\/th>\n<th>Activated Receptors<\/th>\n<th>Main Effects<\/th>\n<th>Riduzione peso (durata)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Semaglutide<\/td>\n<td>GLP-1<\/td>\n<td>Satiety\u2191, delayed gastric emptying\u2193, improved glycemic control<\/td>\n<td>~15% (\u224868 weeks)*<\/td>\n<\/tr>\n<tr>\n<td>Tirzepatide<\/td>\n<td>GLP-1 + GIP<\/td>\n<td>&gt; Appetite\u2193, glucose\u2193, enhanced insulin response\u2191<\/td>\n<td>~22,5% (\u224872 weeks)*<\/td>\n<\/tr>\n<tr>\n<td><strong>Retatrutide<\/strong><\/td>\n<td><strong>GLP-1 + GIP + glucagon<\/strong><\/td>\n<td>All of the above + increased energy expenditure\u2191; marked reduction in liver fat<\/td>\n<td><strong>~24% (48 weeks)<\/strong><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p class=\"note\" style=\"font-size: 0.95em;\">Values derived from different clinical studies (not head-to-head). Retatrutide data from NEJM 2023; tirzepatide and semaglutide from SURMOUNT and STEP trials.<\/p>\n<h3><strong>Clinical status and registries<\/strong><\/h3>\n<p class=\"translation-block\"><p>\n  Retatrutide remains under clinical investigation. Multiple <strong>Phase 3 trials<\/strong> are ongoing in various populations (obesity, type 2 diabetes, weight maintenance, comorbid conditions).\n  For official protocols, see:\n<\/p>\n<ul>\n  <li><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05931367\" target=\"_blank\" rel=\"nofollow noopener\">NCT05931367<\/a><\/li>\n  <li><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05929079\" target=\"_blank\" rel=\"nofollow noopener\">NCT05929079<\/a><\/li>\n  <li><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT07035093\" target=\"_blank\" rel=\"nofollow noopener\">NCT07035093<\/a><\/li>\n<\/ul><\/p>\n<h3>References<\/h3>\n<ol>\n<li><a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2301972\" target=\"_blank\" rel=\"nofollow noopener\">NEJM 2023 \u2014 Retatrutide per l\u2019obesit\u00e0 (fase 2)<\/a> \u00b7 <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37366315\/\" target=\"_blank\" rel=\"nofollow noopener\">PubMed 37366315<\/a><\/li>\n<li><a href=\"https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736%2823%2901053-X\/fulltext\" target=\"_blank\" rel=\"nofollow noopener\">Lancet 2023 \u2014 Retatrutide in T2D (fase 2)<\/a> \u00b7 <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37385280\/\" target=\"_blank\" rel=\"nofollow noopener\">PubMed 37385280<\/a><\/li>\n<li><a href=\"https:\/\/www.nature.com\/articles\/s41591-024-03018-2\" target=\"_blank\" rel=\"nofollow noopener\">Nature Medicine 2024 \u2014 Sottostudio MASLD<\/a> \u00b7 <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/38858523\/\" target=\"_blank\" rel=\"nofollow noopener\">PubMed 38858523<\/a><\/li>\n<li><a href=\"https:\/\/www.clinicaltrials.gov\/study\/NCT05931367\" target=\"_blank\" rel=\"nofollow noopener\">ClinicalTrials.gov \u2014 Studi di fase 3<\/a><\/li>\n<\/ol>\n<p class=\"disclaimer translation-block\">Pepticore Aminos products are intended exclusively for research and laboratory use (<em>Research Use Only<\/em>). Not for human or animal consumption, nor for clinical or therapeutic use.<\/p><\/p>\n<\/section>","protected":false},"excerpt":{"rendered":"<p data-start=\"348\" data-end=\"511\">Retatrutide is a tri-agonist peptide targeting GLP-1, GIP, and glucagon receptors, an advanced evolution of tirzepatide, studied in research settings for its role in metabolism and body weight regulation.<\/p>","protected":false},"featured_media":11399,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}}},"product_brand":[50],"product_cat":[49,70,67],"product_tag":[],"class_list":["post-12237","product","type-product","status-publish","has-post-thumbnail","product_brand-pepticore-aminos","product_cat-metabolismo-controllo-peso","product_cat-peptidi-liofilizzati-fiale","product_cat-supporto-immunitario","desktop-align-center","tablet-align-center","mobile-align-center","first","instock","shipping-taxable","purchasable","product-type-simple"],"acf":[],"_links":{"self":[{"href":"https:\/\/pepticoreaminos.us\/en\/wp-json\/wp\/v2\/product\/12237","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pepticoreaminos.us\/en\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/pepticoreaminos.us\/en\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/pepticoreaminos.us\/en\/wp-json\/wp\/v2\/comments?post=12237"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pepticoreaminos.us\/en\/wp-json\/wp\/v2\/media\/11399"}],"wp:attachment":[{"href":"https:\/\/pepticoreaminos.us\/en\/wp-json\/wp\/v2\/media?parent=12237"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/pepticoreaminos.us\/en\/wp-json\/wp\/v2\/product_brand?post=12237"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/pepticoreaminos.us\/en\/wp-json\/wp\/v2\/product_cat?post=12237"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/pepticoreaminos.us\/en\/wp-json\/wp\/v2\/product_tag?post=12237"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}